Depression is a major health problem worldwide. Most prescribed anti-depressants, the selective serotonin reuptake inhibitors (SSRI) show limited efficacy and delayed onset of action, partly due to the activation of somatodendritic 5-HT 1A -autoreceptors by the excess extracellular serotonin (5-HT) produced by SSRI in the raphe nuclei. Likewise, 5-HT 1A receptor (5-HT 1A R) gene polymorphisms leading to high 5-HT 1A -autoreceptor expression increase depression susceptibility and decrease treatment response. In this study, we report on a new treatment strategy based on the administration of small-interfering RNA (siRNA) to acutely suppress 5-HT 1A -autoreceptor-mediated negative feedback mechanisms. We developed a conjugated siRNA (C-1A-siRNA) by covalently binding siRNA targeting 5-HT 1A receptor mRNA with the SSRI sertraline in order to concentrate it in serotonin axons, rich in serotonin transporter (SERT) sites. The intracerebroventricular (i.c.v.) infusion of C-1A-siRNA to mice resulted in its selective accumulation in serotonin neurons. This evoked marked anti-depressant-like effects in the forced swim and tail suspension tests, but did not affect anxiety-like behaviors in the elevated plus-maze. In parallel, C-1A-siRNA administration markedly decreased 5-HT 1A -autoreceptor expression and suppressed 8-OH-DPAT-induced hypothermia (a pre-synaptic 5-HT 1A R effect in mice) without affecting post-synaptic 5-HT 1A R expression in hippocampus and prefrontal cortex. Moreover, i.c.v. C-1A-siRNA infusion augmented the increase in extracellular serotonin evoked by fluoxetine in prefrontal cortex to the level seen in 5-HT 1A R knockout mice. Interestingly, intranasal C-1A-siRNA administration produced the same effects, thus opening the way to the therapeutic use of C-1A-siRNA. Hence, C-1A-siRNA represents a new approach to treat mood disorders as monotherapy or in combination with SSRI.
Introduction
Major depression is a severe and heterogeneous psychiatric disease with high, increasing prevalence and socio-economic impact. [1] [2] [3] The serotonergic system is implicated in the etiology and treatment of mood disorders. 2 Most prescribed anti-depressants, the selective serotonin (5-HT) reuptake inhibitors (SSRI) and the dual 5-HT and norepinephrine reuptake inhibitors block physiological reuptake mechanisms in serotonergic axons, and thereby increase extracellular 5-HT concentration to activate post-synaptic 5-HT receptors (5-HT 1A R) required for clinical effects. However, this process is severely compromised by the simultaneous activation of somatodendritic 5-HT 1A -autoreceptors in the midbrain raphe nuclei. 5-HT 1A -autoreceptor activation reduces serotonergic activity and forebrain 5-HT release, an effect contrary to that required for therapeutic response. [4] [5] [6] Hence, the limited clinical efficacy of 5-HT-enhancing drugs and their delayed action are partly due to this negative feedback mechanism. Upon chronic treatment, 5-HT 1A -autoreceptors desensitize, leading to the recovery of serotonergic activity and 5-HT release. 5, 6 Individuals with elevated density or activity of 5-HT 1A -autoreceptors are more susceptible to mood disorders and respond poorly to antidepressants. [7] [8] [9] 5-HT 1A R antagonists might thus be useful to improve anti-depressant therapy by preventing the 5-HT 1A -autoreceptor-mediated negative feedback. However, the activation of post-synaptic 5-HT 1A R is a necessary step for anti-depressant effects, 10 which limits the usefulness of this strategy. Thus, unlike the non-selective 5-HT 1A R/-adrenoceptor antagonist pindolol 11, 12 (with a preferential action at 5-HT 1A -autoreceptors), 13, 14 the selective 5-HT 1A R antagonist DU-125530 does not enhance clinical fluoxetine effects (Scorza et al., in preparation).
In this study, we report on a new anti-depressant strategy, based on the use of small-interfering RNA (siRNA) targeted to serotonin neurons, to selectively reduce the expression and function of pre-synaptic (but not post-synaptic) 5-HT 1A R. We have developed a conjugated 5-HT 1A R siRNA (C-1A-siRNA) directed to serotonin neurons, by covalently binding 5-HT 1A R siRNA molecules to the SSRI sertraline. Our working hypotheses were: a) the presence of sertraline would allow the selective accumulation of C-1A-siRNA in serotonin neurons and b) the selective 5-HT 1A -autoreceptor silencing would have anti-depressant effects due to the increased signaling and preservation of post-synaptic 5-HT 1A R activity.
Materials and methods

Animals
Male C57BL/6J mice (Charles River) and male homozygous 5-HT 1A R knockout (1A-KO) mice on the same background 15 were used. Mice (10-15-week old) were housed under controlled conditions (22 ± 1 1C; 12 h light/dark cycle) with food and water available ad libitum. Animal procedures were conducted in accordance with standard ethical guidelines (European Union regulations L35/118/12/1986) and approved by the local ethical committee.
siRNAs Four unmodified siRNAs (nt: 633-651, 852-870, 1889-1907 and 2167-2185, GenBank accession #NM_008308) targeting the 5-HT 1A R (1A-siRNA1 to 1A-siRNA4) were chosen for in vivo studies and administered as a mixture, containing an equal amount of each siRNA duplex. In addition, an unrelated siRNA duplex with no homology to mouse genome was used as negative control (nonsense siRNA -ns-siRNA). All siRNAs, consisted of two complementary 21-nucleotide RNA strand with 3 0 dTdT overhangs and were prepared according to the manufacturer's protocol (Ambion, Madrid, Spain). Conjugated siRNA against 5-HT 1A R (C-1A-siRNA) and conjugated nonsense siRNA (C-ns-siRNA) were synthesized by nLife Therapeutics, S.L. (La Coruñ a, Spain) as described (International patent application PCT/EP2011/056270). Each specific siRNA sequence against 5-HT 1A R (1A-siRNA1 to 1A-siRNA4) and ns-siRNA was designed to carry a substitution in each 5 0 -end strand ( Figure 1a ). Conjugated singlestrand oligonucleotides were purified by reversephase high-performance liquid chromatography. Fractions containing full-length oligonucleotides were pooled, desalted, lyophilized and characterized by MALDI-TOF. Complementary strands were annealed in an isotonic RNA-annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH pH = 7.4, 2 mM magnesium acetate), pre-incubated by 1 min at 90 1C, centrifuged for 15 s and incubated 1 h at 37 1C. Annealed products were high-performance liquid chromatography purified and siRNA-containing fractions were lyophilized. Purity was > 92%. Similarly to unmodified siRNAs, conjugated siRNAs were used in vivo as a mixture consisting of an equal amount of each C-1A-siRNA.
For experiments involving localization of C-1A-siRNA after intracerebroventricular (i.c.v.) infusion, each C-1A-siRNA molecule was additionally bound to biotin in the anti-sense strand. This was performed by a biotinylation reaction of the conjugate's OH-free end in its terminal C18 spacer.
We used a second strategy to generate a construct with a stronger stability against ribonucleases by the standard phosporamidite chemistry 16, 17 as described (International patent application PCT/EP2011/ 056270). A sertraline-conjugated ns-oligonucleotide (single-strand 18-mer oligonucleotide nonsense sequence, with 2 0 -O-methyl ribonucleotides at positions 1-3 and 16-18, and a DNA gap of 12 nucleobases) was synthesized with a Cy3 label at 3 0 attached by a phosphodiester linkage. This was coupled to sertraline to examine the penetration into serotonin neurons after i.c.v. infusion.
A siRNA targeting b-galactosidase (b-Gal-128) bearing a motif eliciting interferon production was also used. 18 Stock solutions of all siRNAs were prepared by re-suspension of the lyophilized product in RNAsefree water and stored at À20 1C until use. siRNA sequences are shown in Supplementary Table S1 .
Treatments
Intracerebral siRNA infusion. Mice were anesthetized (pentobarbital, 40 mg kg À1 , i.p.) and silica capillary microcannulae (110 mm-OD, 40 mm-ID; Polymicro Technologies, Madrid, Spain) were stereotaxically implanted into dorsal raphe nucleus (DR; coordinates in mm: anteroposterior-AP, -4.5; mediolateral-ML, -1.0; dorsoventral-DV, -4.4; with a lateral angle of 201) or in dorsal third ventricle (D3V; AP, -2.0; ML, 0; DV, -2.1). 19 Some animals were also implanted with a microdialysis probe in medial prefrontal cortex (mPFC) (see below). siRNA microinfusion was performed with a perfusion pump at 0.5 ml min À1 20-24 h after surgery in awake mice. siRNAs targeting 5-HT 1A R, b-galactosidase or nonsense were prepared in artificial cerebrospinal fluid (125 mM NaCl, 2.5 mM KCl, 1.26 mM CaCl 2 and 1.18 mM MgCl 2 with 5% glucose) and infused at doses of 10 or 30 mg of siRNA per mouse. Intra-DR siRNA infusion was repeated 24 h later (1-ml aliquots; two administrations in total), while i.c.v. infusion was performed only once into the D3 V (2.5-ul aliquots). Controls and 1A-KO mice received aCSF.
Intranasal siRNA administration. Pentobarbitalanesthetized mice were positioned lying on their backs. Phosphate buffered saline (PBS) or conjugated siRNAs (C-ns-siRNA and C-1A-siRNA prepared in PBS) were slowly dropped alternatively into each nostril with a micropipette tip in 5-ml aliquots. Total administered doses were 30 or 100 mg of conjugated siRNAs.
RNA isolation and quantitative RT-PCR analysis
After 24-48 h the last administration of vehicle or siRNA, mice were killed and brains were removed. Midbrain sections containing the raphe nuclei (1-mm thick) were dissected out using a Mouse Brain Matrix (Ted Pella, Madrid, Spain), quickly frozen on dry ice and stored at À80 1C. Total RNA was isolated with Trizol solution (Invitrogen, Barcelona, Spain). Complementary DNA synthesis was performed using Retro-tools two step kits (Biotools B & M labs SA, Madrid, Spain). Quantitative RT-PCR (7900HT Fast Real-Time PCR System, Applied Biosystems, Madrid, Spain) was performed using Power SYBR Green PCR Master Mix (Applied Biosystems) in 20 ml of reaction mix. Cycle threshold values were calculated using AbiPrism SDS 2.1 software (Applied Biosystems). Data were normalized to the amount of cyclophilinA cDNA. Results were expressed as the unitary ratio versus vehicle controls. Primer sequences are given in Supplementary Table S1 .
Tissue preparation for in situ hybridization and receptor autoradiography Mice were killed by pentobarbital overdose and the brains rapidly removed, frozen on dry ice and stored at À20 1C. Tissue sections, 14-mm thick, were cut using a microtome-cryostat (HM500 OM, Microm, Walldorf, Germany), thaw-mounted onto 3-aminopropyltriethoxysilane-coated slides (Sigma-Aldrich, Madrid, Spain) and kept at À20 1C until use.
In situ hybridization For 5-HT 1A R mRNA, three oligonucleotides were used simultaneously, complementary to bases: 1-48, 763-810 and 1219-1266 (GenBank accession #NM_012585). These probes were synthesized with a 380 Applied Biosystem DNA synthesizer. Labeling of the probes and in situ hybridization procedures were carried out as described previously. [20] [21] [22] Hybridized sections were exposed to Biomax MR film (Kodak, Sigma-Aldrich, Madrid, Spain) for 2-3 weeks with intensifying screens.
Receptor autoradiography
The autoradiographic binding assays for 5-HT 1A and 5-HT 1B receptors and serotonin transporter (SERT) 20, 23, 24 were performed using the following radioligands: (a) [ ), respectively (Amersham-GE Healthcare, Barcelona, Spain and Perkin-Elmer, Madrid, Spain). 8-OH-DPAT, isoproterenol, pargyline and 5-HT were from Sigma-Aldrich, and fluoxetine was from Tocris. Experimental conditions are summarized in Supplementary Table S2 . Tissues were exposed to Biomax MR film (Kodak) together with 3 H-Microscales standards (Amersham-GE Healthcare). All experimental and control brains within a group were processed in duplicate and exposed to films as a batch.
Films were analyzed by microdensitometry using a computer-assisted image analyzer (AIS, Imaging Research, St Catherines, Ontario, Canada). 5-HT 1A R mRNA and 5-HT 1B binding sites in selected brain regions were measured in the respective autoradiograms to obtain relative optical densities. For 5-HT 1A R and SERT binding, the system was calibrated with 3 H-Microscales standards to obtain fmol mg À1 protein equivalents from relative optical densities data. AIS system was also used to acquire pseudocolor images. Black and white photographs were taken from autoradiograms using a Wild 420 microscope (Leica, Heerbrugg, Germany) equipped with a Nikon DXM1200 F digital camera and ACT-1 Nikon software, Soft Imaging System Gmbh, Mü nster, Germany. Images were processed with Photoshop (Adobe Systems, Mountain View) by using identical values for contrast and brightness. 3%. Finally, sections were mounted with Mowiol (Calbiochem, San Diego, CA, USA). Samples were analyzed using a Leica spectral confocal microscope; (Wetzlar, Germany) data were sequentially collected from each channel, merged by Leica Confocal Software (Wetzlar, Germany) and 3D projections (maximal, average and transparent) were made from z-series. Pictures were generated using Photoshop.
Intracerebral microdialysis
Extracellular 5-HT concentration was measured by in vivo microdialysis as previously described. 20 Briefly, one concentric dialysis probe (cuprophan; 1 mm-long) was implanted in mPFC (AP, 2.2; ML, -0.2; DV, -3.4) 19 of pentobarbital-anaesthetized mice. Experiments were performed 48-72 h after surgery. To assess 8-OH-DPAT effects on extracellular 5-HT, 1 mM citalopram (SSRI; Lundbeck A/S, Valby, Copenhagen) was added to artificial cerebrospinal fluid. 25 The artificial cerebrospinal fluid was pumped at 2.0 ml min À1 (WPI model sp220i) and 30-min samples were collected. 5-HT concentrations were analyzed by high-performance liquid chromatography-amperometric detection (Hewlett-Packard 1049; þ 0.6 V, Palo Alto, CA, USA) with detection limits of 1.5 fmol sample À1 . Baseline 5-HT levels were calculated as the average of the four pre-drug samples. Correct probe placement was verified using cresyl-violet staining.
Behavioral and physiological assessments
Mice were tested at 24-72 h after treatments. Elevated plus-maze (EPM) and tail suspension tests (TST) were always conducted in this order, with 1 day between tests. All tests were performed between 1000 and 1500 hours. On test days, animals were transported to the dimly illuminated behavioral laboratory and were left undisturbed for at least 1 h before testing.
8-OH-DPAT-induced hypothermia. Body temperature was measured intrarectally using a lubricated probe inserted B2 cm and a digital thermometer (AZ9882, Panlab, Barcelona, Spain). Mice were singly housed in clean cages for 20 min before measurements, and then two baseline temperature measurements were taken. After 10 min, animals received 8-OH-DPAT 1 mg kg À1 i.p., and body temperature was recorded every 15 min for a total of 120 min. Data are presented as a change from the final baseline measurement. Tail suspension test. Mice were suspended 30 cm above the bench by adhesive tape placed approximately 1 cm from the tip of the tail. Mice were monitored and recorded using a video camera system (Smart, Panlab), and the time spent immobile was recorded for 6 min.
Forced swim test (FST)
. Mice were individually placed into a clear cylinder (15 cm diameter, 30 cm height) containing 20 cm of water maintained at 24-25 1C, essentially as described by Porsolt et al.
26
In this test, time of immobility was scored in 2-mm bins for a total of 6 min using a video camera system (Smart, Panlab).
Statistical analysis
Data are expressed as means±s.e.m. Data were analyzed with Student's t-test, one-or two-way analysis of variance, as appropriate, followed by post-hoc test (Newman-Keuls). The level of significance was set at P < 0.05 (two tailed).
Results
Selective silencing of 5-HT 1A -autoreceptor expression
The potential of siRNA-based gene silencing in vivo has been limited by the lack of safe delivery to specific target cells. 27 Previously, 28 we established that local infusion of four siRNA sequences directed toward 5-HT 1A R (1A-siRNA) into the mice DR reduced 5-HT 1A -autoreceptor expression and function without affecting post-synaptic 5-HT 1A R, evoking a robust and rapid antidepressant-like effect. We therefore used the same 1A-siRNA sequences to construct C-1A-siRNA. Sense and antisense strands were chemically conjugated in each 5 0 -end strand, whereas the sense strand was covalently bound to the SSRI-sertraline (Figure 1a ). This modification was intended to direct C-1A-siRNA molecules to 5-HT axons, extremely rich in axonal varicosities ( > 10 After 48 h stereotaxic infusion in the D3 V (30 mg per mouse, as in receptor expression and functional experiments; see below), the C-1A-siRNA construct was detected in midbrain serotonergic neuropil, rich in dendrites and initial axonal segments (Figure 1b,  Supplementary Figure S1 ). In contrast, C-1A-siRNA was undetectable in dorsal hippocampal neurons, located much closer to the infusion site (Supplementary Figure S2) . Additional experiments using a Cy3-coupled, sertraline-conjugated -18-mer oligonucleotide (see Material and methods) showed that 24 h after its infusion into the D3 V (30 mg), the Cy3-labeled oligonucleotide was found in the cytoplasm of TPHpositive midbrain serotonin neurons (Supplementary Figure S3) .
Next, we evaluated whether the i.c.v. infusion of C-1A-siRNA could selectively silence the 5-HT 1A R gene in 5-HT neurons, as observed after local infusion of unmodified 1A-siRNA. 28 Mice were stereotaxically injected into D3 V with: (a) vehicle, (b) unmodified nonsense siRNA (ns-siRNA), (c) unmodified 1A-siRNA, (d) C-ns-siRNA or (e) C-1A-siRNA (30 mg of each siRNA). Histological examination at 1-3 days post-administration revealed that 5-HT 1A R mRNA and binding densities were significantly decreased in the dorsal (40% versus control) and median raphe (30%) nuclei of C-1A-siRNA-treated mice (Figure 2a , c and Supplementary Figure S4) .
A similar decrease was produced by intra-DR infusion of the same unmodified 1A-siRNA sequences (Supplementary Figure S5) . Likewise, local 1A-siRNA and C-1A-siRNA infusion reduced comparably 5-HT 1A R binding density in the DR (Supplementary Figure S6) , indicating that sertraline conjugation did not alter 1A-siRNA capacity to knockdown 5-HT 1A R.
In contrast, C-1A-siRNA infusion into D3 V did not affect post-synaptic 5-HT 1A R density in forebrain (Figure 2b, d and Supplementary Figure S7a ), nor that of other genes expressed by 5-HT neurons (SERT and 5-HT 1B R) of the same mice (Figure 3a-c) . Likewise, C-1A-siRNA sequences did not upregulate inflammatory cytokines (tumor necrosis factor a and interferong) or apoptotic genes (BAX), while the immunostimulatory activity of b-galactosidase-siRNA sequence (used as positive control) dramatically increased tumor necrosis factor a and interferon-g expression (Figure 3d-f) , indicating that 5-HT 1A -autoreceptor silencing was specifically mediated by an RNA interference (RNAi) mechanism.
Effects of C-1A-siRNA on serotonergic function The physiological consequences of 5-HT 1A -autoreceptor silencing were examined using the hypothermia response induced by the selective 5-HT 1A R agonist, 8-OH-DPAT, an effect mediated exclusively by presynaptic 5-HT 1A R in mice. Table S3 ). However, 8-OH-DPAT administration (0.5 mg kg À1 , i.p.) reduced extracellular 5-HT concentration in mPFC of vehicle (56% of baseline) and C-ns-siRNA-treated mice (60%), but not in C-1A-siRNA-treated (88%) and 1A-KO mice (99%) (Figure  2f, Supplementary Figure S8b) .
To assess the involvement of SERT as a gate for the accumulation of C-1A-siRNA in 5-HT neurons, mice were pretreated with sertraline (20 mg kg À1 , i.p.; 3 h before the i.c.v. C-1A-siRNA infusion). These mice displayed the fall in 5-HT release and body temperature as did controls, whereas those treated with C-1A-siRNA alone did not respond to 8-OH-DPAT in both experimental approaches (Figure 2e-f, Supplementary  Figure S8 ). This indicates that C-1A-siRNA requires functional SERT sites to silence 5-HT 1A -autoreceptor expression.
C-1A-siRNA evokes anti-depressant-like responses
To explore the behavioral effects of 5-HT 1A -autoreceptor knockdown, we examined the antidepressant-and anxiety-like responses using the FST, tail suspension test (TST) and EPM paradigm. Mice infused with C-1A-siRNA (30 mg) into the D3 V displayed a marked reduction of immobility time in FST compared with controls ( Figure 4a) . Moreover, C-1A-siRNA-treated mice showed a significantly lower immobility than controls in the TST, as did 1A-KO mice (Figure 4b ). A quantitative difference between both groups was noted, likely due to the partial knockdown of 5-HT 1A -autoreceptors in C-1A-siRNA-treated mice and total absence in 1A-KO mice. Fluoxetine administration (10 mg kg À1 , i.p.), used as a positive control, also reduced immobility in the FST and TST (Figure 4a and b) . In contrast, control and C-1A-siRNA-treated mice behaved comparably in the EPM, with equal number of entries and time spent in the open arms. 1A-KO mice showed a clear anxiogenic profile, as previously described 15, 31 (Figure 4c) . At the neurochemical level, fluoxetine (20 mg kg À1 , i.p.) increased extracellular 5-HT concentration in mPFC significantly more in C-1A-siRNA (272% of baseline) and 1A-KO mice (230%) than in controls (vehicle: 138%; C-ns-siRNA: 150%), indicating that C-1A-siRNA-induced reduction in 5-HT 1A -autoreceptors augments SSRI effects (Figure 4d ).
Intranasal C-1A-siRNA administration reduces 5-HT 1A -autoreceptor expression and induces anti-depressant effects The above findings support the potential of C-1A-siRNA as a new anti-depressant strategy, either as monotherapy or in combination with 5-HT-enhancing drugs. However, its therapeutic use is limited by the lack of a suitable route to brain. We therefore examined the potential of the non-invasive intranasal route, as described before. [32] [33] [34] Intranasal C-1A-siRNA administration (30 mg per mouse, as in i.c.v. studies) reduced 5-HT 1A R mRNA and binding density (27%) in the DR, but not in post-synaptic sites in the same mice (Figure 5a-d, Supplementary Figure S7b) . Unlike in controls (vehicle and C-ns-siRNA), 8-OH-DPAT administration did not reduce body temperature and 5-HT release in mice treated intranasally with C-1A-siRNA (Figure 5e and f) .
Given the smaller effect size of 30 mg intranasal C-1A-siRNA on 5-HT 1A -autoreceptor expressioncompared with i.c.v. infusion-we conducted behavioral experiments using 30 and 100 mg of intranasal C-1A-siRNA. Both doses significantly reduced immobility in the TST, with a greater effect of the 100 mg dose (Figure 5g) . Similarly, intranasal C-1A-siRNA (100 mg) evoked a reduction of immobility time in the FST, which was significantly lower than that seen in controls (Figure 5h ). Neither dose affected anxietylike behavior as assessed with EPM test (data not shown).
Discussion
The present findings show that C-1A-siRNA can be used to efficiently and selectively silence 5-HT 1A -autoreceptor expression and function in vivo. This represents a new therapeutic approach in neuropsychopharmacology, based on the use of RNAi. Hence, i.c.v. and intranasal C-1A-siRNA infusion (i) reduced 5-HT 1A -autoreceptor expression, without affecting that of post-synaptic 5-HT 1A R, (ii) suppressed the hypothermia and fall in 5-HT release induced by 8-OH-DPAT; (iii) evoked a marked anti-depressant- n = 14-15) . Two-way analysis of variance showed a significant effect of group (F 1,27 = 12.98, P < 0.001), time (F 2,54 = 150.05, P < 0.0001) and interaction (F 2,54 = 3.18, P < 0.05). A significantly greater reduction of the immobility in C-1A-siRNA-treated mice versus controls was observed for the total period (0-6 min) (P < 0.01; Student's t-test). A comparable anti-depressant response was observed after acute selective serotonin reuptake inhibitors fluoxetine administration to control C57BL/6J mice (10 mg kg À1 , i.p. 30 min before FST) (n = 12-13). Effect of group (F 1,23 = 5.18, P < 0.05) and time (F 2,46 = 66.94, P < 0.0001). Student's t-test was used to assess the action of fluoxetine for the total observation period (0-6 min). *P < 0.05, **P < 0.01, ***P < 0.001 versus respective controls. (b) C-1A-siRNAtreated mice also showed a reduced immobility in the tail suspension test (TST), as did constitutive 1A-KO mice (n = 12-18). One-way analysis of variance showed a significant effect of group (F 2,47 = 18.64, P < 0.001). Acute fluoxetine administration (10 mg kg À1 , i.p. 1 h before TST) produced a similar anti-depressant response (n = 7). **P < 0.01, ***P < 0.001 versus vehicle mice, ## P < 0.01 versus C-1A-siRNA mice. (c) Unlike 1A-KO mice, vehicle and C-1A-siRNA mice behaved similarly in the elevated plus-maze (n = 12-18). One-way analysis of variance indicated a group effect on entries ( . Two-way analysis of variance showed a significant effect of group (F 2,13 = 34.21, P < 0.001), time (F 4,52 = 59.30, P < 0.001) and interaction (F 8,52 = 10.89, P < 0.001). ***P < 0.001 versus control groups. (f) Reduced extracellular serotonin in mPFC of controls, but not in C-1A-siRNA mice after 8-OH-DPAT administration (0.5 mg kg À1 , i.p.) (n = 4-6). Significant effect of group (F 2,12 = 8.22, P < 0.01), time (F 14,168 = 7.56, P < 0.001) and interaction (F 28,168 = 2.28, P < 0.001). **P < 0.01 versus controls. (g) Single intranasal C-1A-siRNA administration (30 or 100 mg) evoked a dose-dependent decreased immobility in the tail suspension test (n = 10-15). One-way analysis of variance showed a significant effect of group (F 2,34 = 8.70, P < 0.001). *P < 0.05, ***P < 0.001 versus vehicle. (h) Mice treated intranasally with C-1A-siRNA (100 mg) displayed a reduced immobility time in the forced swim test compared with vehicle-treated controls (n = 13-16). Two-way analysis of variance showed a significant effect of group (F 1,27 = 9.27, P < 0.01) and time (F 2,54 = 102.95, P < 0.0001). Student's t-test was used to assess the action of C-1A-siRNA for the total observation period (0-6 min). **P < 0.01 versus vehicle. Values are mean±s.e.m. like response in the FST and TST, and (iv) augmented the SSRI-induced elevation of extracellular 5-HT.
siRNAs are effective, safe and well tolerated in mice and non-human primates. Although they are used therapeutically in other medical areas, their applicability to brain diseases has been hampered by the difficulty to target selected neuronal populations and by the lack of adequate delivery methods. 27 The present results represent a major advance in this field given the selective targeting of 5-HT 1A R expressed in 5-HT neurons after i.c.v. and intranasal administration. Although further investigations are required to examine the exact mechanism(s) used by C-1A-siRNA to accumulate into 5-HT neurons, available evidence suggests that C-1A-siRNA can be internalized via SERT, similarly to SSRI 35 to reach the somatodendritic region of serotonergic neurons via retrograde axonal transport. This view is supported by (i) the selective presence of sertraline-conjugated C-1A-siNA and the C-ns-oligonucleotide in midbrain serotonergic neuropil and cell bodies, respectively, (ii) its selective action on 5-HT 1A -autoreceptors (far from the infusion site), (iii) the lack of effect on hippocampal 5-HT 1A R, much closer to the D3V, and (iv) the prevention of C-1A-siRNA effects by prior SERT blockade. The present procedure offers unprecedented efficacy and cellular selectivity, compared with previous siRNA conjugation methods used in vivo. 27, [36] [37] [38] Hence, the 40% knockdown of 5-HT 1A -autoreceptors produced by single-point administration of 30 mg C-1A-siRNA is comparable to previous results using prolonged infusion of unmodified siRNA to silence monoamine transporters (400 mg day À1 for 1-2 weeks; 2.8-5.6 mg in total, that is 90-180-fold the dose used herein). 39, 40 Our results agree with previous observations on the detrimental role of 5-HT 1AÀ autorerceptors in depression. Human neuroimaging studies have associated high 5-HT 1A -autoreceptor levels with a poor amygdale reactivity. 41 Likewise, genetic studies link 5-HT 1A R mutations leading to high levels of 5-HT 1A -autoreceptors with higher incidence of mood disorders and poorer response to anti-depressants. 7 In rodents, disruption of the 5-HT 1A -autoreceptor-mediated negative feedback with 5-HT 1A R antagonists enhances SSRI effects. 5, 6 Clinically, the non-selective 5-HT 1A R antagonist pindolol augments and accelerates SSRI effects, likely by a preferential interaction with 5-HT 1A -autoreceptors. 11, 12, 42 The present data support that C-1A-siRNA could be used to acutely suppress 5-HT 1A -autoreceptor function, without the need to wait for anti-depressant-induced desensitization, thus optimizing antidepressant action.
Our results also agree with those found recently using conditional knockout mice for pre-synaptic 5-HT 1A R. 43 Both studies indicate that the selective, yet partial, reduction of 5-HT 1A -autoreceptor expression with unchanged post-synaptic 5-HT 1A R expression evokes anti-depressant-like behavior and augments SSRI effects. Interestingly, the RNAi strategy can be applied in adult mice, without the unwanted neurodevelopmental effects associated to 5-HT 1A R suppression. 44 Although further improvements are required, the intranasal route offers a first potential way for C-1A-siRNA delivery to brain. This route allowed the same effects than the i.c.v. infusion, yet with a slightly smaller effect size, likely due to the dilution of C-1A-siRNA during brain entry. Once crossed the semi-permeable nasal blood-brain barrier, C-1A-siRNA molecules may reach the dense plexus of serotonergic axons in outer layers of the olfactory bulb, anatomically connected with olfactory regions. 45 In summary, our results show for the first time the feasibility of using RNAi strategies for the treatment of mood disorders. The excellent cellular selectivity and efficacy obtained with acute C-1A-siRNA treatment indicate that this may be a new approach to treat mood disorders and open the way to develop RNAi-based therapeutic classes to silence genes, or variant alleles refractory to classical pharmacological treatments.
